Synairgen (SNG)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

161.00p
   
  • Change Today:
    -1.30p
  • 52 Week High: 224.66p
  • 52 Week Low: 77.00p
  • Currency: UK Pounds
  • Shares Issued: 201.34m
  • Volume: 640,586
  • Market Cap: £324.16m
  • RiskGrade: 510

Latest ShareCast News

Synairgen drug proves effective against Covid variants in lab tests

By Abigail Townsend

Date: Monday 24 May 2021

(Sharecast News) - A drug being developed by Synairgen to treat severe lung infections has shown promising laboratory results against emerging variants of Covid-19, the biotech announced on Monday.

Synairgen confirms start of dosing in Covid-19 trial

By Josh White

Date: Monday 15 Feb 2021

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Monday that dosing has started in the inhaled interferon beta formulation 'SNG001' sub-study of the 'ACTIV-2' phase 2 and 3 trial, evaluating patients with mild-to-moderate Covid-19 symptoms not yet requiring hospitalisation.

Synairgen enters clinical trial deal with US government

By Josh White

Date: Monday 25 Jan 2021

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced a clinical trial agreement on Monday, to include its inhaled interferon beta-1a treatment 'SNG001' in the ACTIV-2/A5401 phase 2 and 3 trial in patients with Covid-19 not yet requiring hospitalisation.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Synairgen Market Data

Currency UK Pounds
Share Price 161.00p
Change Today -1.30p
% Change -0.80 %
52 Week High 224.66p
52 Week Low 77.00p
Volume 640,586
Shares Issued 201.34m
Market Cap £324.16m
RiskGrade 510

Synairgen Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
48.64% above the market average48.64% above the market average48.64% above the market average48.64% above the market average48.64% above the market average
92.00% above the sector average92.00% above the sector average92.00% above the sector average92.00% above the sector average92.00% above the sector average
Price Trend
0.84% below the market average0.84% below the market average0.84% below the market average0.84% below the market average0.84% below the market average
19.35% above the sector average19.35% above the sector average19.35% above the sector average19.35% above the sector average19.35% above the sector average
Income
5.46% above the market average5.46% above the market average5.46% above the market average5.46% above the market average5.46% above the market average
63.64% above the sector average63.64% above the sector average63.64% above the sector average63.64% above the sector average63.64% above the sector average
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Synairgen Dividends

No dividends found

Trades for 23-Sep-2021

Time Volume / Share Price
16:29 307 @ 161.00p
16:29 245 @ 161.00p
16:29 25 @ 161.00p
16:29 8,588 @ 161.39p
16:29 449 @ 161.00p

Synairgen Key Personnel

CEO Richard J Marsden
Finance Director John C Ward

Top of Page